Clinical Trials Logo

Filter by:
NCT ID: NCT00214773 Completed - Clinical trials for Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)

Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

Start date: July 2005
Phase:
Study type: Observational

The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing information for optimizing patient care based on aggregate data; to characterize the clinical response to long-term Naglazyme® (galsulfase) treatment; to further characterize the long-term safety of Naglazyme® treatment.

NCT ID: NCT00214695 Completed - Clinical trials for End Stage Renal Disease

A Subjective Evaluation of Inflow Pain Associated With the Use of an Experimental Solution for Peritoneal Dialysis

Start date: May 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the inflow pain using an experimental peritoneal dialysis solution compared to a current solution for the management of end stage renal disease (ESRD) in peritoneal dialysis (PD) patients.

NCT ID: NCT00212615 Completed - Clinical trials for C04.588.274.476.411.307

XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer

Start date: February 2004
Phase: Phase 2/Phase 3
Study type: Interventional

XELOX (Capecitabine and Oxaliplatin) is an effective and convenient regimen for patients with metastatic colorectal cancer. Chronomodulated therapy may reduce toxicity. Patients will be randomized to standard XELOX (Capecitabine 1000 mg/m² in the morning and 1000 mg/m² in the evening days 1-14 and short term Oxaliplatin 130 mg/m² day 1 in 30 minutes) or chronomodulated XELOX (Capecitabine 400 mg/m² in the morning and 1600 mg/m² in the evening days 1-14 and short term Oxaliplatin 130 mg/m² day 1 in 30 minutes). Bloodsamples will be collected and frozen and later examined for potential predictive factors

NCT ID: NCT00211237 Completed - Cancer Clinical Trials

CAFE Study - Cancer Patient Fracture Evaluation

CAFE
Start date: May 2005
Phase: N/A
Study type: Interventional

The primary objective of this study is to evaluate the safety and effectiveness of balloon kyphoplasty treatment for painful, acute, vertebral compression fractures (VCFs) as compared to standard non-surgical therapy in patients with cancer.

NCT ID: NCT00211159 Completed - Alzheimer's Disease Clinical Trials

OmegAD (Omega-3 and Alzheimer's Disease)

Start date: December 2000
Phase: N/A
Study type: Interventional

Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be due to a deficiency in the brain of a fatty acid named DHA. The aim of this trial is to see if dietary supplementation with a preparation, rich in DHA, will halt cognitive impairment in AD patients

NCT ID: NCT00211068 Completed - Clinical trials for Pure Red-cell Aplasia

A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa

Start date: March 2004
Phase: Phase 4
Study type: Observational

The purpose of this study is to collect historical occurrences of risk factors that are potentially associated with the development of anti-erythropoietin (EPO) antibody positive pure red cell aplasia (PRCA) in participants with chronic kidney disease who have been recently treated with epoetin alfa (EPREX).

NCT ID: NCT00211042 Completed - Clinical trials for Pure Red-cell Aplasia

A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment

Start date: February 2004
Phase: Phase 4
Study type: Observational

The purpose of this study is to investigate the relationship of anti-erythropoietin antibodies to the clinical course and outcome of pure red cell aplasia (PRCA) in participants currently or previously treated with recombinant human erythropoietin.

NCT ID: NCT00209924 Completed - Primary Insomnia Clinical Trials

A Study of Gaboxadol in Primary Insomnia

Start date: April 2004
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy safety and tolerability of gaboxadol in primary insomnia.

NCT ID: NCT00209846 Completed - Primary Insomnia Clinical Trials

A Study of Gaboxadol in Primary Insomnia

Start date: June 2004
Phase: Phase 3
Study type: Interventional

To evaluate the safety and tolerability of gaboxadol in primary insomnia.

NCT ID: NCT00209430 Completed - Clinical trials for Coronary Artery Disease

Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography

Start date: August 2005
Phase: Phase 4
Study type: Interventional

The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.